W Schuyler Jones, Hillary Mulder, Lisa M Wruck, Michael J Pencina, Sunil Kripalani, Daniel Muñoz, David L Crenshaw, Mark B Effron, Richard N Re, Kamal Gupta, R David Anderson, Carl J Pepine, Eileen M Handberg, Brittney R Manning, Sandeep K Jain, Saket Girotra, Danielle Riley, Darren A DeWalt, Jeff Whittle, Ythan H Goldberg, Veronique L Roger, Rachel Hess, Catherine P Benziger, Peter Farrehi, Li Zhou, Daniel E Ford, Kevin Haynes, Jeffrey J VanWormer, Kirk U Knowlton, Jennifer L Kraschnewski, Tamar S Polonsky, Dan J Fintel, Faraz S Ahmad, James C McClay, James R Campbell, Douglas S Bell, Gregg C Fonarow, Steven M Bradley, Anuradha Paranjape, Matthew T Roe, Holly R Robertson, Lesley H Curtis, Amber G Sharlow, Lisa G Berdan, Bradley G Hammill, Debra F Harris, Laura G Qualls, Guillaume Marquis-Gravel, Madelaine F Modrow, Gregory M Marcus, Thomas W Carton, Elizabeth Nauman, Lemuel R Waitman, Abel N Kho, Elizabeth A Shenkman, Kathleen M McTigue, Rainu Kaushal, Frederick A Masoudi, Elliott M Antman, Desiree R Davidson, Kevin Edgley, James G Merritt, Linda S Brown, Doris N Zemon, Thomas E McCormick, Jacqueline D Alikhaani, Kenneth C Gregoire, Russell L Rothman, Robert A Harrington, Adrian F Hernandez
BACKGROUND: The appropriate dose of aspirin to lower the risk of death, myocardial infarction, and stroke and to minimize major bleeding in patients with established atherosclerotic cardiovascular disease is a subject of controversy. METHODS: Using an open-label, pragmatic design, we randomly assigned patients with established atherosclerotic cardiovascular disease to a strategy of 81 mg or 325 mg of aspirin per day. The primary effectiveness outcome was a composite of death from any cause, hospitalization for myocardial infarction, or hospitalization for stroke, assessed in a time-to-event analysis...
May 27, 2021: New England Journal of Medicine